Loading... Please wait...

K1NGSGUARD

  • kings guard
Price:
$49.99
Brand:
Weight:
0.30 LBS
Shipping:
Calculated at checkout
Quantity:


Product Description

K1NG’S are either born or made.  If you are not among the select few natural born K1NG’S, you are left to forge your our own destiny.  The pursuit to reach the ranks of the elite often leads to the use anabolic/androgenic compounds.  Although that approach can be an effective means to achieve your goals, it is not without risk.  The use of androgenic compounds has been associated with numerous toxic side-effects including hepatotoxicity (toxic to the liver) and deleterious cardiovascular changes. The most widely reported of these latter changes include the development of adverse lipid profiles and hypertension.  Another aspect of our health that is typically neglected by bodybuilders supplementing with androgenic compounds is immune support.  These effects can occur even if you maintain a healthy diet.  Are you adequately protected?  Would a K1NG leave himself exposed?  

 

If you have royal ambitions you need a commensurate defense, befitting of a K1NG.  Fortunately, the Olympus Labs R&D division are comprised of natural born K1NGS who have graciously agreed to bestow their royal knowledge on the masses.  Thus Olympus Labs issues the following royal decree: Elite athletes will be henceforth be protected by K1NG’S GUARD.  No longer will you left without an adequate defense on a cycle.  K1NG’S GUARD is the ultimate natural on-cycle health supplement that will shield your body from the adverse side effects from androgenic compounds.  

 

Contrary to competing on-cycle products, K1NG’S GUARD goes beyond just liver or blood pressure protection. K1NG’S GUARD employs five royal matrices to eliminate the threat to your health.  As you would expect from Olympus Labs, K1NG’S GUARD demonstrates our commitment to Innovation, Value & Results with clinically proven compounds, including 5 patented ingredients.  The Royal Liver & Kidney SHIELD Matrix mitigates the largest threat on cycle, liver toxicity, with 400mg of Silymarin Phytosome®, 150mg of Picroliv and 300mg of TUDCA.  In addition, Silymarin Phytosome® maintains an adequate acid-alkaline concentration of sodium and potassium in the blood to prevent kidney congestion.  

 

However, it is not enough to just address hepatotoxicity.  Maintenance of healthy plasmatic lipid (dietary fat) levels are imperative in order to protect your heart and arteries.  The Royal Cardioprotective/Antiatherogenic Matrix consisting of 550mg of Bergavit ® and 475mg of Rutin will lower bad cholesterol to mitigate the risk of cardiovascular disease or atherosclerosis, the narrowing and hardening of the arteries.  Androgenic compounds increases blood pressure via the renin-angiotensin-aldosterone system to levels that cannot be mitigated by reducing stimulant and sodium intake.  K1NG’S GUARD provides real defense through The Royal Blood Pressure Defense Matrix with 300mg of MegaNatural® and 500 mg of Aged garlic bulb extract.

 

The final two matrices address health impacts that are commonly ignored on cycle.  The Royal Immune System Rise Immunomodulation builds upon  the immunomodulating effects of aged garlic extract with 15mg of MaitakeGold 404® to protect your immune system.  Finally, The Royal Anti-Blood Thickening Complex consisting of 500mg Naringin and 800mg White Willow Bark thins the blood to mitigate the risk of  acute thrombosis, the formation of a blood clot which obstructs the flow of blood.  

 

If you aspire to join the elite class and become a K1NG, you need the protection befitting of royalty. Olympus Labs facilitates your transition with the ultimate all-in-one on-cycle support in the form of  K1NG’S GUARD.  It can also be a beneficial supplement to support your health and recovery in PCT combined with K1NG’S  BLOOD.  The risk is too great to rely on an inferior defense so arm yourself properly with K1NG’S GUARD.

 

The Royal Liver & Kidney SHIELD Matrix

It is common knowledge that the vast majority of androgenic compounds are harsh on the body.  Several of the most potent compounds are hepatotoxic, meaning they are damaging or destructive to liver cells.  This is one of the largest risk areas when on cycle.  A true K1NG never leaves his weakest point exposed, therefore K1NG’S GUARD protects your liver with a Royal Shield in the form of 400mg of Silymarin Phytosome®, 150mg of Picroliv and 300mg of TUDCA.  Olympus Labs provides with you the best defence against toxins with these three potent ingredients.  In addition, Silymarin Phytosome® can prevent kidney congestion or kidney stones, caused when your kidneys are unable to maintain the right acid-alkaline concentration of sodium and potassium in the blood and other fluids.  .

 

Silymarin Phytosome®

Silymarin Phytosome® is a complex of seven flavonolignans, most notably silybin, silydianin, and silycristin, extracted from Silybum marianum fruits.  Silymarin is the active ingredient of the plant that has traditionally been used to handle congestion in the kidneys, spleen, and veins. More recently Silymarin has been studied as a liver protectant.  Unfortunately, silymarin, and even more silybin, have poor intestinal absorption that hinder their efficacy.  Silymarin Phytosome® resolves that issue since Phytosomes are better able to transition from a hydrophilic environment into the lipid-friendly environment of the outer cell membrane, and from there into the cell, finally reaching the blood.  Silymarin Phytosome® utilizes a phospholipid-complexed process that binds Silymarin to Soybean Phospholipids in a 1:2 ratio.  Olympus Labs fans that have supplemented with EP1C UNLEASHED and DERMASTRENGTH UNLEASHED, which utilizes a similar phospholipid-complex,  know first hand how effective it can be.  

 

A clinical study was designed to evaluate the protective effect of silymarin against the suspected renal and hepatic injury induced with long term use of non-steroidal anti-inflammatory drugs (NSAIDs).  220 patients with osteoarthritis were randomized into 5 groups and treated with either 300mg/day of silymarin alone, 20mg/day of piroxicam alone,  15mg/day of meloxicam alone or the combination of each of them with silymarin for 8 weeks.  The results indicated that using NSAIDs alone produced elevation in the markers of renal and hepatic damage that can be successfully prevented or reversed when silymarin adjunctly used with them.

 

Since a complex of silybin (IdB 1016), the main active component of silymarin, and phosphatidylcholine has shown greater oral bioavailability in animal models a study was carried out to assess its pharmacokinetic profile in humans.  Nine healthy volunteers participated in the study which measured plasma silybin levels after administration of single oral doses of IdB 1016 and silymarin (equivalent to 360 mg silybin).  Although absorption was rapid with both preparations, the bioavailability of IdB 1016 was much greater than that of silymarin, as indicated by higher plasma silybin levels at all sampling times after intake of the complex. Regardless of the preparation used, the terminal half-life was relatively short (generally less than 4 h).  In a subsequent study, 9 healthy volunteers received IdB 1016 (120 mg b.i.d., expressed as silybin equivalents) for 8 consecutive days. The plasma silybin level profiles and kinetic parameters on day 1 were similar to those determined on day 8.  Taken together these results demonstrate the complexation with phosphatidylcholine in IdB 1016 greatly increases the oral bioavailability of silybin, believed to be facilitated by improved passage across the gastrointestinal mucosa.

 

An in-vivo study was carried out to compare the effect of Silybin, the main component of silymarin, used as single substance to a silybin–phosphatidylcholine complex (SilPho) in gastric and liver cancer cells (MKN28 and HepG2).  SilPho and new silybin glycoconjugates did not affect cell viability, while silybin induced about 50% cell death in both MKN28 and in HepG2 cells.  Pre-treatment of cells with silybin and new silybin glycoconjugates (before oxidative stress induction) did not affect cell viability, while SilPho had a protective effect.  Exposure of MKN28 cells to oxidative stress caused a two-fold increase in cellular MDA concentration compared to untreated cells. Moreover, pre-treatment with SilPho,significantly prevented oxidative stress-induced increase in cellular Malondialdehyde,  but not that result was not duplicated with silybin, . Moreover, silybin induced apoptosis potentiated by oxidative stress, while SilPho did not induce any effect. Oxidative stress caused cell death primarily by necrosis, antagonized by SilPho. These results demonstrate that a phosphatidylcholine complex with a flavonoid from the Silybum marianum fruit is far superior to that flavonoid as a single substance.

 

Picroliv

Picroliv is a glycoside fraction from roots of Picrorhiza kurroa, an Ayurvedic herb.  The plant is known to be highly bitter, in fact its name is derived from the Greek word picros which means ‘bitter’.  It has been used in the treatment of upper respiratory tract, fevers, dyspepsia, chronic diarrhea, and scorpion stings.  However, it has traditionally used to treat liver disorders since it has potent hepatoprotective (protective of the liver) properties when ingested prior to or taken after exposure to a toxin.  Notably, Picroliv has been validated as protective against alcohol induced liver damage.  Picroliv has also shown choleretic effect,  anti-cholestatic and anti-viral effects.   It also has the ability to stimulate the immune system and is devoid of any significant CNS and CVS, autonomic and other systemic activity.

 

Cellular adaptation to hypoxia involves regulation of specific genes such as vascular endothelial growth factor (VEGF), erythropoietin (EPO) and hypoxia inducible factor (HIF)-1 . In this study, we have evaluated the protective effect of picroliv (a purified iridoid glycoside fraction from roots of Picrorhiza kurrooa with hepatoprotective, anti-inflammatory and antioxidant properties) against hypoxic injury by examining lactate dehydrogenase (LDH) release in Hep 3B and Glioma cells. The expression of hypoxia regulated genes, VEGF and HIF-1 was studied in human umbilical vein endothelial cells (HUVEC), Hep 3B and Glioma cells. Picroliv reduced the cellular damage caused by hypoxia as revealed by a significant reduction in LDH release compared to untreated control. The expression of VEGF and HIF-1 subunits (HIF-1alpha and HIF-1beta) was enhanced by treatment with picroliv during normoxia and hypoxia in HUVEC and Hep 3B cells and on reoxygenation the expression of these genes was significantly reduced as revealed by mRNA analysis using RT-PCR. Simultaneous treatment with picroliv during hypoxia inhibited VEGF and HIF-1 expression in Glioma cells whereas the expression was not reduced by picroliv treatment during reoxygenation as evidenced by both RT-PCR and Northern hybridization. VEGF expression as revealed by immunofluorescence studies correlates well with the regulations observed in the mRNA expression. We have also examined the kinase activity of tyrosine phosphorylated proteins and protein kinase C (PKC) in Glioma cells treated with picroliv during hypoxia/reoxygenation. A selective inhibition of protein tyrosine kinase activity leading to tyrosine dephosphorylation of several proteins including 80 kd protein, and a reduction in PKC was seen in cells treated with picroliv and hypoxia. These findings suggest that picroliv may act as a protective agent against hypoxia/reoxygenation induced injuries, and the underlying mechanism may involve a novel signal transduction pathway.

 

A clinical study assessed the comparative antioxidant effect of picroliv, a standardized iridoid glycoside fraction of Picrorhiza kurroa and silymarin, a well known standard hepatoprotective, on aflatoxin B(1),  a potent hepatotoxic and hepatocarcinogenic mycotoxin, induced lipid-peroxidation in rat liver and kidney. Marked increases in lipid peroxide levels and a concomitant decrease in enzymic antioxidant levels were observed in aflatoxin B(1) (2 mg/kg, i.p) -toxicated rats, while drug (picroliv and silymarin both) treatment reversed the condition to near normal levels. These results demonstrate that Picroliv has  comparable.efficacy to silymarin which has been extensively studied.

 

TUDCA

Tauroursodeoxycholic acid, most commonly referred to as TUDCA, is a water soluble bile salt.  It naturally formed in the body when regular bile salts reach the intestines, they are metabolized by bacteria into ursodeoxycholic acid (UDCA) and then later bound to a taurine molecule to form TUDCA.  Bile salts are chemical produced in the liver and stored in the gallbladder which serve a critical role in the digestion of fats and helps to eliminate toxins from the body.  Bile salts are opposed by bile acids, a group of molecular species of acidic steroids with peculiar physical-chemical and biological characteristics.  At high concentrations they become toxic to mammalian cells, and their presence is pertinent in the pathogenesis of several liver diseases and colon cancer.  Bile acid cytotoxicity has been related to membrane damage, but also to non detergent effects, such as oxidative stress and apoptosis.  The use of pro-hormones typically result in an unhealthy increase in bile acid concentrations which can lead to cholestasis, the reduction or impairment of bile flow. TUDCA can counteract this toxicity and thus indirectly protect cells from death.

 

The protective effect of ursodeoxycholic acid, both free, taurine and glycine conjugated,was evaluated against hepatotoxic bile acids such as chenodeoxycholic acid and its taurine amidate  compared with the cholic and taurocholic acid effect.  Taurochenodeoxycholic acid and chenodeoxycholc acid caused cholestasis and liver damage associated with a decreased bile flow, total and individual bile acids secretion accompanied by a biliary leakage of lactate dehydrogenase and alkaline phosphatase enzymes. Tauroursodeoxycholic acid, glycine ursodeoxycholic acid, ursodeoxycholic acid and taurocholic acid, on the contrary, were choleretic, inducing an opposite effect on biliary parameters. Simultaneous infusion of taurochenodeoxycholic acid and the protective bile acid resulted in a functional and morphological improvement of the above parameters in the following order: glycine ursodeoxycholic acid > tauroursodeoxycholic acid > ursodeoxycholic acid followed by taurocholic acid.  Cholic acid was found to be ineffective.

These results demonstrate the protective effect of glycine ursodeoxycholic acid, ursodeoxycholic acid and tauroursodeoxycholic acid. The protective mechanism is believed to be facilitated by the transport of the toxic bile acid into bile.

 

A clinical study sought to assess the metabolism of tauroursodeoxycholic acid (TUDCA) and its effects on the bile acid pool of patients with asymptomatic/mildly symptomatic primary biliary cirrhosis. Patients were randomly assigned to three groups that orally consumed 500, 1000, or 1500 mg/day of tauroursodeoxycholate for six months.  During tauroursodeoxycholate administration, the proportion of total ursodeoxycholate in bile reached mean (SEM) 34.4 (4.5)%, 32.8 (2.8)%, and 41.6 (3.0)% with doses of 500, 1000, and 1500 mg/day, respectively. Significant decreases in the proportions of chenodeoxycholate and cholate resulted. The glycine/taurine ratio of the biliary bile acid pool decreased from 1.9 at baseline, to 1.1 with the highest dose. Ursodeoxycholate in bile was conjugated with glycine and taurine, indicating that tauroursodeoxycholate undergoes significant deconjugation and reconjugation during its enterohepatic recycling. The proportion of lithocholate in bile remained unchanged. Fasting serum conjugated ursodeoxycholate concentration positively correlated with the tauroursodeoxycholate dose, and the increased proportion of ursodeoxycholate was accompanied by substantial decreases in the endogenous bile acids. These findings suggest that even at a low dose, TUDCA can significantly reduce endogenous bile acids.

 

The Royal Cardioprotective/Antiatherogenic Matrix:

It is common for bodybuilders to increase their caloric intake on cycle to gain muscle mass.  That diet will naturally include include a higher amount of fat than usual with the androgenic compounds helping to metabolize the incremental fat.  However, many pro-hormone users fail to consider maintenance of healthy plasmatic lipid levels.  The Royal Cardioprotective/Antiatherogenic Matrix with 550mg of Bergavit ® and 475mg of Rutin will protect your heart and arteries.  Bergavit ® lowers bad cholesterol to mitigate the risk of cardiovascular disease or atherosclerosis, the narrowing and hardening of the arteries.  Rutin has been shown to prevent and reverse symptoms of metabolic syndrome, changes in hepatic and cardiovascular structure and function, oxidative stress and inflammation in the liver and heart.

 

Bergavit ®

Bergavit ® is a patented extract of the main flavonoids found in bergamot juice.  Bergamot, also referred to as Citrus bergamia, has been used for centuries in folk medicine to support healthy plasmatic lipid levels.  Specifically, Bergavit ® can benefit cardiovascular health by promoting a normal plasmatic lipid pattern, by improving the ratio of high density lipoprotein (HDL) or “good cholesterol” to low density lipoprotein (LDL) also known as “bad cholesterol”.  Too much LDL over time can  lead to the narrowing and hardening of arteries, known as atherosclerosis which can lead to heart disease or a heart attack.  Bergavit ® also lowers small, dense low-density lipoprotein-cholesterol (sdLDL-C), a recently recognised indicator of cardiovascular disease risk.  It has been found that men have higher sdLDL levels than pre-menopausal women so it is important that those levels are managed appropriately.   Bergavit ® is also a supplement well known for its antioxidant properties and its ability to mitigate inflammation.  

 

A clinical study was conducted to investigate the effects of a Bergamot extract on cardio-metabolic parameters, including plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis.  Eighty subjects (42 men and 38 women, mean age: 55 ± 13 years) with moderate hypercholesterolemia, having plasma LDL-cholesterol concentrations between 160 and 190 mg/dl (between 4.1 and 4.9 mmol/l) participated. A Bergamot-derived extract (Bergavit R(®)) was given at a fixed dose daily (150 mg of flavonoids, with 16% of neoeriocitrin, 47% of neohesperidin and 37% of naringin) for 6 months.  After 6 months, Bergavit R(®) reduced total cholesterol (from 6.6 ± 0.4 to 5.8 ± 1.1 mmol/l, p < 0.0001), triglycerides (from 1.8 ± 0.6 to 1.5 ± 0.9 mmol/l, p = 0.0020), and LDL-cholesterol (from 4.6 ± 0.2 to 3.7 ± 1.0 mmol/l, p < 0.0001), while HDL- cholesterol increased (from 1.3 ± 0.2 to 1.4 ± 0.4 mmol/l, p < 0.0007). In addition, a significant increase in LDL-1 (from 41.2 ± 0.2 to 49.6 ± 0.2%, p < 0.0001) was accompanied by decreased small, dense LDL-3, -4, and 5 particles (from 14.5 ± 0.1 to 9.0 ± 0.1% p < 0.0001; 3.2 ± 0.1 to 1.5 ± 0.1% p = 0.0053; 0.3 ± 0.0% to 0.1 ± 0.0% p = 0.0133, respectively).  Carotid intima-media thickness (CIMT) a widely used marker for atherosclerosis was also decreased from 1.2 ± 0.4 to 0.9 ± 0.1 mm (p < 0.0001).  These results demonstrate that Bergavit R(®) (Bergamot juice extract) supplementation can significantly reduce plasma lipids and improve the lipoprotein profile.  

 

Rutin

Rutin is a non-nutritive component of several foods, including apples, citrus, buckwheat, and onions. It is a glycoside of quercetin, a supplement well known for its antioxidant properties and its ability to mitigate inflammation.  Rutin has been shown, in animal models, to prevent and reverse symptoms of metabolic syndrome, including abdominal fat pads, glucose tolerance, changes in hepatic and cardiovascular structure and function, oxidative stress and inflammation in the liver and heart.  

In an in vitro study, human macrophages, a line of white blood cells, were treated with rutoside (RU) and then analyzed for inflammation-related gene expression using a specific array.  RU inhibited inflammation-related gene expression in activated human macrophages and the release of nitric oxide, tumor necrosis factor-alpha, interleukin (IL)-1, and IL-6 from these cells. RU was also injected into adjuvant-induced arthritic rats.  In the rat model, RU inhibited clinical signs of chronic arthritis, correlating with decreased levels of inflammatory cytokines detected in rat cell lines.  Therefore, RU may be a hold promise as a clinical treatment to reduce inflammatory manifestations in human arthritis and other inflammatory diseases.

 

In another clinical trial, employing both in vitro and in vivo approaches, the ability of rutin in blocking macrophage-mediated inflammation and high fat diet-induced obesity and fatty liver was investigated.  It was found that cells pre-exposed to Rutin suppressed mRNA levels of pro-inflammatory cytokines, a range of proteins that can have an inhibiting effect on the immune system.  The suppression was correlated with a decrease in transcription of genes responsible for ER stress and production of reactive oxygen species. In vivo, rutin was observed to be protect mice from high fat diet-induced obesity, fatty liver and insulin resistance. The protective effects were associated with lack of hypertrophy and crown-like structures in the white adipose tissue, decreased mRNA levels of marker genes for macrophages including F4/80, Cd11c and Cd68, and repressed transcription of genes involved in chronic inflammation such as Mcp1 and Tnfα in white adipose tissue. In addition, rutin increased the expression of genes responsible for energy expenditure in brown adipose tissue including Pgc1α and Dio2. Rutin was also observed to suppress transcription of Srebp1c and Cd36 in the liver, leading to a blockade of fatty liver development.  These results align with other studies on Rutin and suggest that supplementation can block macrophage-mediated inflammation and inflammation-induced obesity and its associated complications.

 

The Royal Blood Pressure Defense Matrix:

It is common knowledge that the use of androgenic compounds raise blood pressure.  This effect is believed to be  triggered via the renin-angiotensin-aldosterone system, which is a hormone system that is involved in the regulation of the plasma sodium concentration and arterial blood pressure.  In addition, research has shown a correlation between very high testosterone levels and hypertension in both males and females.  How do you manage blood pressure on cycle?  If you are just reducing your stimulant and sodium intake, you are not doing enough.  K1NG’S GUARD provides a real defense with 300mg of MegaNatural® and 500 mg of Aged garlic bulb extract.  Both ingredients provide several health benefits including antiviral, antibacterial and cholesterol lowering properties.  However, the main impetus for their inclusion in K1NG’S GUARD was the exceptional data on cardiovascular protection.  Furthermore, both MegaNatural® and Aged garlic bulb extract have been studied as a treatment for hypertension, a condition of persistent high blood pressure that affects approximately 30% of adults worldwide.

MegaNatural® BP Seed Extract

Grape Seed Extract (GSE) is a supplement derived from grape seeds that contains a mixture of tannins and procyanidins. Procyanidins in GSE are chains of catechin molecules, which are the polyphenolic compounds found in teas.  GSE has been found to be an effective antioxidant and vasodilator that has historically been used as a treatment for several medical conditions including high blood pressure, high cholesterol, poor circulation, constipation and gastrointestinal disorders.  Olympus Labs uses MegaNatural® BP in K1NG’S BLOOD which is a high-quality Grape Seed Extract with clinically shown benefits.  MegaNatural® BP is shown in studies to be superior to other grape seed extracts in protecting blood serum components against oxidation.  It has also been shown through clinical studies to possess greater antioxidant capacity than vitamins C & E and β-carotene.  In addition, research has shown GSE induces endothelium-dependent relaxation that is then mediated by activation of the PI3K/Akt signalling pathway through a redox-sensitive mechanism, resulting in phosphorylation of endothelial NO (eNOS).

 

 

Given that 31% of the adult population of the United States over the age of 18 years old is affected by pre-hypertension (BP of 120-139 / 80-89 mmHg), safe treatments are highly sought after.  For that reason, two placebo-controlled human clinical trials conducted by researchers at the Department of Preventative Cardiology from the Davis School of Medicine at the University of California verified that MegaNatural®-BP supports blood pressure within the normal range.  These studies evaluated subjects with blood pressure levels in the normal to prehypertensive ranges. One study  involving patients with metabolic syndrome, showed incidental blood pressure reductions, averaging 12 mmHg for systolic and 8 mmHg for diastolic pressures. In another study, participants with prehypertension took 300 mg of MegaNatural®-BP once a day for two months, and blood pressure monitoring averaged in systolic readings 8 mmHg lower and diastolic pressure lower by 5 mmHg. These studies demonstrated that MegaNatural®-BP may offer a significant benefit for people with technically healthy blood pressure that typically ranges on the upper end of normal, a condition known as “prehypertension.”

 

Aged garlic extract

Garlic has been associated with improving several health parameters, including being accredited as a powerful immune booster.  The immunomodulating effects of garlic are achieved by increasing macrophage activity, natural killer cells, and the production of T and B cells.  It also possesses antiviral, antibacterial, anti-fungal properties, the impetus behind garlic’s traditional use as a  treatment for infections. Clinical trials have shown garlic to significantly reduce the number, duration, and severity of upper respiratory infections.  There also been research that has associated garlic supplementation with a blood pressure (BP)-lowering effect of clinical significance in hypertensive patients. Although, there are several garlic preparations on the market, including garlic powder, garlic oil and raw or cooked garlic, aged garlic extract was the preparation of choice for BP treatment.  Aged garlic extract has a higher safety profile than other garlic preparations, and does not cause bleeding problems if taken with other blood-thinning medicines.  In addition, it contains the active and stable component S-allylcysteine, which has been the focus of research as a treatment for high cholesterol and cancer.

 

A meta-analysis of 20 randomized controlled trials (RCTs) published between 1955 and December 2013 on the effect of garlic preparations on blood pressure was completed.  Across the 20 trials involving 970 participants, a mean ± SE decrease in systolic blood pressure (SBP) of 5.1 ± 2.2 mm Hg (P < 0.001) and a mean ± SE decrease in diastolic blood pressure (DBP) of 2.5 ± 1.6 mm Hg (P < 0.002) was measured compared with placebo. Subgroup analysis of trials in hypertensive subjects (SBP/DBP ≥140/90 mm Hg) at baseline revealed a larger significant reduction in SBP of 8.7 ± 2.2 mm Hg (P < 0.001; n = 10) and in DBP of 6.1 ± 1.3 mm Hg (P < 0.001; n = 6).  A previously published meta-analysis on the effect of garlic on blood lipids, which included 39 primary RCTs and 2300 adults treated for a minimum of 2 wk, suggested garlic to be effective in reducing total and LDL cholesterol by 10% if taken for >2 mo by individuals with slightly elevated concentrations [e.g., total cholesterol >200 mg/dL (>5.5 mmol/L)].  The  meta-analysis concluded that garlic supplements have the potential t


Find Similar Products by Category


Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!


Customers Who Viewed This Product Also Viewed